Quantcast
Home > Quotes > ONCS
ONCS

OncoSec Medical Incorporated Common Stock (ONCS) Quote & Summary Data

$0.7942
*  
0.0007
0.09%
Get ONCS Alerts
*Delayed - data as of Dec. 14, 2018 13:53 ET  -  Find a broker to begin trading ONCS now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ONCS Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 0.7912 / $ 0.7943
1 Year Target
3
Today's High / Low
$ 0.7955 / $ 0.74
Share Volume
559,033
50 Day Avg. Daily Volume
2,500,024
Previous Close
$ 0.7949
52 Week High / Low
$ 2.21 / $ 0.677
Market Cap
51,099,745
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.21

Intraday Chart

Shares Traded

Share Volume:
559,033
50 Day Avg. Daily Volume:
2,500,024

Trading Range

The current last sale of $0.7942 is 17.31% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.7955 $ 2.21
 Low: $ 0.74 $ 0.677

Company Description (as filed with the SEC)

We are a biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer. Our core platform technology, ImmunoPulse®, is a drug-device therapeutic modality comprised of a proprietary intratumoral electroporation delivery device. The ImmunoPulse® platform is designed to deliver plasmid DNA-encoded drugs directly into a solid tumor and promote an immunological response against cancer. The ImmunoPulse® device can be adapted to treat different tumor types, and consists of an electrical pulse generator, a reusable handle and disposable applicators. Our lead product candidate, ImmunoPulse® IL-12, uses our electroporation device to deliver a plasmid DNA-encoded interleukin-12 ("IL-12"), called tavokinogene telseplasmid ("TAVO"), with the aim of reversing the immunosuppressive microenvironment in the treated tumor.  ... More ...  


Risk Grade

Where does ONCS fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 0.795
Open Date:
Dec. 14, 2018
Close Price:
$ 0.7949
Close Date:
Dec. 13, 2018

Consensus Recommendation

Analyst Info